A truncated form of IKKα is responsible for specific nuclear IKK activity in colorectal cancer

Nuclear IKKα regulates gene transcription by phosphorylating specific substrates and has been linked to cancer progression and metastasis. However, the mechanistic connection between tumorigenesis and IKKα activity remains poorly understood. We have now analyzed 288 human colorectal cancer samples a...

ver descrição completa

Detalhes bibliográficos
Autores: Margalef González, Pol, 1985-, Fernández Majada, Vanessa, Villanueva, Alberto, Garcia Carbonell, Ricard, Iglesias Coma, Mar, López Muñoz, Laura, Martínez Iniesta, María, Villà i Freixa, Jordi, Mulero, María Carmen, Andreu García, Montserrat, Torres, Ferran, Mayo, Marty W., Bigas Salvans, Anna, Espinosa Blay, Lluís
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2012
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/24642
Acesso em linha:http://hdl.handle.net/10230/24642
http://dx.doi.org/10.1016/j.celrep.2012.08.028
Access Level:acceso abierto
Palavra-chave:Tumors
Còlon -- Càncer
Descrição
Resumo:Nuclear IKKα regulates gene transcription by phosphorylating specific substrates and has been linked to cancer progression and metastasis. However, the mechanistic connection between tumorigenesis and IKKα activity remains poorly understood. We have now analyzed 288 human colorectal cancer samples and found a significant association between the presence of nuclear IKK and malignancy. Importantly, the nucleus of tumor cells contains an active IKKα isoform with a predicted molecular weight of 45 kDa (p45-IKKα) that includes the kinase domain but lacks several regulatory regions. Active nuclear p45-IKKα forms a complex with nonactive IKKα and NEMO that mediates phosphorylation of SMRT and histone H3. Proteolytic cleavage of FL-IKKα into p45-IKKα is required for preventing the apoptosis of CRC cells in vitro and sustaining tumor growth in vivo. Our findings identify a potentially druggable target for treating patients with advance refractory CRC.